Alexion Pharmaceuticals Inc. (ALXN)’s Financial Results Comparing With Midatech Pharma Plc (NASDAQ:MTP)

Since Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) and Midatech Pharma Plc (NASDAQ:MTP) are part of the Biotechnology industry, they are influenced by compare. The influences particularly affect the profitability, analyst recommendations, risk, dividends, institutional ownership, earnings and valuation of both companies.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Alexion Pharmaceuticals Inc. 127 5.70 N/A 1.40 91.79
Midatech Pharma Plc 2 0.00 N/A -0.85 0.00

Table 1 showcases the gross revenue, earnings per share (EPS) and valuation of Alexion Pharmaceuticals Inc. and Midatech Pharma Plc.


Table 2 hightlights the return on assets, net margins and return on equity of the two companies.

Net Margins Return on Equity Return on Assets
Alexion Pharmaceuticals Inc. 0.00% 4.5% 3%
Midatech Pharma Plc 0.00% 0% 0%

Analyst Recommendations

In next table is delivered Alexion Pharmaceuticals Inc. and Midatech Pharma Plc’s ratings and recommendations.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Alexion Pharmaceuticals Inc. 0 1 4 2.80
Midatech Pharma Plc 0 0 0 0.00

$163.33 is Alexion Pharmaceuticals Inc.’s consensus price target while its potential upside is 42.71%.

Insider and Institutional Ownership

The shares of both Alexion Pharmaceuticals Inc. and Midatech Pharma Plc are owned by institutional investors at 96.9% and 0% respectively. Insiders owned 0.2% of Alexion Pharmaceuticals Inc. shares. Comparatively, 32.1% are Midatech Pharma Plc’s share owned by insiders.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Alexion Pharmaceuticals Inc. -3.92% -6.6% 2.58% 4.03% 4.53% 31.89%
Midatech Pharma Plc -21.05% -30.38% 48.92% -56.58% -79.38% 6.45%

For the past year Alexion Pharmaceuticals Inc. has stronger performance than Midatech Pharma Plc


Alexion Pharmaceuticals Inc. beats on 9 of the 9 factors Midatech Pharma Plc.

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. It also provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia (HPP); and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. In addition, the company conducts Phase III clinical trials for Soliris (eculizumab) for the treatment of myasthenia gravis and neuromyelitis optica spectrum disorder; and Phase II clinical trials for antibody mediated rejection in presensitized renal transplant patients. Further, it develops cPMP (ALXN 1101) that is in Phase II/III trial for treating metabolic disorders; SBC-103, which is in Phase I/II clinical trials for the treatment of metabolic disorders; ALXN 1210 (IV) that is in Phase III clinical trials for the treatment of PNH and aHUS; and ALXN 1210, which is in Phase I clinical trials to evaluate subcutaneous delivery. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other health care providers, as well as governments and government agencies in the United States, Europe, the Asia Pacific, and internationally. Alexion Pharmaceuticals, Inc. has agreements with X-Chem Pharmaceuticals (X-Chem) to identify novel drug candidates from X-Chem's proprietary drug discovery engine; and Moderna Therapeutics, Inc. (Moderna) that provides the option to purchase drug products for the development and commercialization of Moderna's messenger RNA therapeutics to treat rare diseases. The company was founded in 1992 and is headquartered in New Haven, Connecticut.

Midatech Pharma PLC, a specialty pharmaceutical company, focuses on the development and commercialization of oncology and other therapeutic products in the United Kingdom, Turkey, other European countries, and the United States. It offers Oravig, an orally dissolving buccal tablet for oral thrush and oropharyngeal candidiasis in adults; Gelclair, an oral rinse gel for the management and relief of pain arising from oral lesions of various etiologies; Zuplenz, an oral soluble film for moderately emetogenic chemotherapy-induced nausea and vomiting, radiotherapy-induced nausea and vomiting, and post-operative nausea and vomiting; and Soltamox, an oral liquid solution of tamoxifen citrate for the prevention of breast cancer. The company also engages in the marketing of Ferralet 90, a prescription iron supplement for the treatment of anemias that are responsive to oral iron therapy; and Aquoral, an artificial saliva spray to provide relief from chemotherapy/radiation therapy. In addition, it is involved in the research and development of various product candidates in the areas of oncology and neuroscience, including ophthalmology; and immunotherapy. Midatech Pharma PLC was founded in 2000 and is headquartered in Abingdon, the United Kingdom.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.